COMPARE · Data as of August 21, 2026
ANIP vs NBIX
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 79.6, NBIX scored 88.0 — NBIX leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
79.6
$77.32 · $1.8B
fundamentals as of
Score gap
8.4
NBIX leads
NBIX
Neurocrine Biosciences, Inc.
88
$152.93 · $15.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestANIP16.8x
- Fastest growthNBIX+34.4%
- Strongest balance sheetNBIX0.12
- Highest qualityNBIX81 / 100
- Largest discount to fair valueANIP-44%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
NBIX
66
Qualityreturns · margins · balance sheet
81
94
Growthrevenue & earnings expansion
96
81
Valuevaluation vs sector peers
88
NBIX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ANIP
NBIX
$173mC
FCF
$870mC+
+30.9%A
Rev
+34.4%A
1.05C
D/E
0.12B+
16.8xA-
P/E
22.4xB+
1.26B
PEG
0.46A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
NBIX
44% below
Price vs fair valuelower is cheaper
11% below
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
+58%
1-yr DCF upside
-6%
+80%
5-yr DCF upside
+12%
+118%
10-yr DCF upside
+46%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
NBIX
Why this score
- Durable high returns
- Diluting shareholders
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. Down 22% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +40% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
NBIXNeurocrine Biosciences, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $15.5b. 18% off the 52-week high of $186.12. Revenue growing +34% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $211.57 (implying +38% upside).
Moat
Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
The model favors NBIX (87.5) over ANIP (85.4) primarily due to NBIX's superior Quality pillar score of 81, reflecting its durable high returns. However, a contrarian might prefer ANIP, which trades at a significant 46% discount to our DCF fair value and implies a negative 6% growth rate, indicating less optimism is priced in. NBIX also carries a "Diluting shareholders" signal, a caution for investors.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and NBIX diverge
On the headline score the gap is 8.4 points in favor of NBIX. The widest single difference is Quality, where NBIX leads by 14.9 points.
- QualityANIP 66.2 · NBIX 81.1NBIX +14.9
- ValueANIP 81.2 · NBIX 87.7NBIX +6.5
- GrowthANIP 93.8 · NBIX 95.9level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.